Sparton Corporation

Sparton — Q1 FY2013 Earnings Presentation

12 slides from Sparton's earnings presentation, Nov 7, 2012

  1. Slide 1: Fiscal 2013 First Quarter Financial Results Conference Call

    Exhibit 99.2 Fiscal 2013 First Quarter Financial Results Conference Call November 7, 2012

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements herein constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. When used herein, words such as “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “w

  3. Slide 3: Today's Agenda

    Today’s Agenda st • 1 Quarter Highlights • Fiscal 2013 First Quarter Results • Segmented Operating Results • Liquidity & Capital Resources • Pending Acquisition of Onyx • Outlook • Q&A 3

  4. Slide 4: 1st Quarter Highlights

    st 1 Quarter Highlights • 14 new business programs with estimated future annualized revenue of $13.4 million. • Quarter end sales backlog of approximately $156.1 million, up 6% from the previous quarter and up 7% increase over a year ago. • Medical business continued sales growth of 2.2% with a gros

  5. Slide 5: Consolidated Financial Results

    Consolidated Financial Results Fiscal 2013 First Quarter (Reported) Quarter ended Sept 30, YoY 2012 2011 Variance Net Sales $ 49,020 $ 51,833 $ (2,813) Gross Profit 7,213 8,344 (1,131) 14.7% 16.1% Selling and Administrative Expense 5,472 5,411 61 Internal R&D Expense 305 398 (93) Amortization of int

  6. Slide 6: Sales & Gross Margin Results: Medical

    Sales & Gross Margin Results Medical SALES 3 Months Ended Sept 30, SEGMENT 2012 % of Total 2011 % Change Medical $ 28,059 57% $ 27,460 2% Complex Systems 12,347 25% 12,560 -2% DSS 13,206 27% 15,287 -14% Eliminations (4,592) -9% (3,474) 32% Totals $ 49,020 100% $ 51,833 -5% GROSS MARGIN 3 Months Ende

  7. Slide 7: Sales & Gross Margin Results: Complex Systems

    Sales & Gross Margin Results Complex Systems SALES 3 Months Ended Sept 30, SEGMENT 2012 % of Total 2011 % Change Medical $ 28,059 57% $ 27,460 2% Complex Systems 12,347 25% 12,560 -2% DSS 13,206 27% 15,287 -14% Eliminations (4,592) -9% (3,474) 32% Totals $ 49,020 100% $ 51,833 -5% GROSS MARGIN 3 Mon

  8. Slide 8: Sales & Gross Margin Results: Defense & Security Systems

    Sales & Gross Margin Results Defense & Security Systems SALES 3 Months Ended Sept 30, SEGMENT 2012 % of Total 2011 % Change Medical $ 28,059 57% $ 27,460 2% Complex Systems 12,347 25% 12,560 -2% DSS 13,206 27% 15,287 -14% Eliminations (4,592) -9% (3,474) 32% Totals $ 49,020 100% $ 51,833 -5% GROSS M

  9. Slide 9: Liquidity & Capital Resources

    Liquidity & Capital Resources Cash Availability ($ in '000) Sep-11 Dec-11 Mar-12 Jun-12 Sep-12 Cash and equivalents 26,984 30,610 26,682 46,950 43,096 LOC Availability 17,533 17,290 16,469 16,277 16,012 Total 44,517 47,900 43,151 63,227 59,108 Debt ($ in '000) Sep-11 Dec-11 Mar-12 Jun-12 Sep-12 Cred

  10. Slide 10: Pending Acquisition of Onyx

    Pending Acquisition of Onyx • $43.25 million purchase price, all-cash transaction. • $50 million of revenue at 18% gross profit (TTM as of June 30, 2012). • Onyx primarily manufactures devices for OEM and emerging technology companies in the Medical and Industrial markets. • Strategic implications…

  11. Slide 11: Fiscal 2013 Outlook

    Fiscal 2013 Outlook • Implementation of the strategic growth plan – Continue to gain traction on a nationally focused direct selling effort – Further leverage Viet Nam as a low cost country alternative and in-region provider – Maintain our level of investment in internal research & development to co

  12. Slide 12: Q&A

    CA) (9) Sparton Q&A 12

Sparton — Q1 FY2013 Earnings Presentation on 6ix